Stem cell research is legal in the United States and most other developed countries, but with significant restrictions that vary by the type of stem cell, the funding source, and the jurisdiction. The biggest legal limits apply specifically to embryonic stem cells, which require the destruction of a human embryo. Research using adult stem cells or induced pluripotent stem cells (cells reprogrammed from adult tissue) faces far fewer legal hurdles.
How U.S. Federal Law Draws the Line
The central legal restriction in the United States is a budget provision known as the Dickey-Wicker Amendment. Renewed every year since 1996 as part of the Department of Health and Human Services spending bill, it prohibits the use of federal funds to create human embryos for research or to conduct research that destroys them. This means the National Institutes of Health cannot pay for the process of extracting stem cells from embryos.
What NIH can fund is research on embryonic stem cell lines that already exist, provided those lines meet specific ethical criteria. The embryos must have been created through IVF for reproductive purposes, no longer needed by the individuals who created them, and donated with voluntary written consent. Researchers working with lines that meet these requirements can receive federal grants to study the cells themselves, even though federal money could not have been used to derive them in the first place.
This distinction matters because it means embryonic stem cell research is not banned. It is simply restricted in how it can be funded. Privately funded research faces no federal prohibition at all. Companies, universities using private endowments, and nonprofit organizations can conduct embryonic stem cell research without running afoul of federal law. As the Baker Institute at Rice University has noted, the U.S. stands out internationally in having no federal restrictions on embryonic stem cell research carried out by private entities.
State Laws Create a Patchwork
Because federal law primarily governs funding rather than outright legality, individual states have stepped in with their own rules, creating a patchwork that ranges from constitutional protections to near-total bans.
On the permissive end, California’s Proposition 71 amended the state constitution to establish a right to conduct stem cell research, including research involving embryonic and adult stem cells. The state backed that right with billions in public funding through the California Institute for Regenerative Medicine. Missouri passed a similar constitutional amendment (Amendment 2) providing legal protection for stem cell research.
On the restrictive end, South Dakota prohibits any research on a living embryo that is not therapeutic to that embryo. Louisiana bars the creation of IVF embryos solely for research purposes. North Dakota, Ohio, and Oklahoma have laws prohibiting various forms of research on embryos or fetal tissue, though the precise scope of each law differs. If you work in stem cell research or are considering participating in a study, the legality depends partly on which state you are in.
Adult and Reprogrammed Stem Cells Face Fewer Limits
Most of the legal controversy centers on embryonic stem cells because extracting them destroys a human embryo. Other types of stem cells sidestep this issue entirely. Adult stem cells, found in bone marrow, fat tissue, and blood, can be harvested without the same ethical concerns. Induced pluripotent stem cells, or iPSCs, are made by reprogramming ordinary adult cells to behave like embryonic ones. Because no embryo is involved, iPSC research is eligible for federal funding without the restrictions imposed by the Dickey-Wicker Amendment.
This legal advantage is one reason iPSC research has expanded rapidly since the technology was developed in 2006. It offers many of the same scientific possibilities as embryonic stem cell research while avoiding the funding and legal barriers.
How Other Countries Handle It
The United Kingdom permits embryonic stem cell research under a licensing system managed by the Human Fertilisation and Embryology Authority. Under the Human Fertilisation and Embryology Act, every fertility clinic and embryo research center must apply for a license, undergo inspections, and follow a detailed code of practice. Licenses last up to four years, with new centers starting at two. The UK approach is more permissive than U.S. federal policy in that it allows government-funded embryo research under regulated conditions, rather than restricting funding for derivation altogether.
Japan has taken one of the most structured approaches to translating stem cell research into treatments. Two laws govern the field: the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act) and the Act on the Safety of Regenerative Medicine (RM Act). The PMD Act created a dedicated approval category for regenerative medicine products and introduced a system of conditional, time-limited approval that lets therapies reach patients faster while safety data continues to be collected. The RM Act classifies regenerative techniques into three risk tiers, with specialized committees reviewing higher-risk treatments. This framework covers both formal clinical trials and treatments offered in private practice outside of insurance coverage.
Stem Cell Clinics and Consumer Protection
Legality in stem cell research extends beyond the lab. Hundreds of clinics across the U.S. market stem cell therapies directly to consumers for conditions like joint pain, neurological disorders, and autoimmune diseases. Many of these treatments have not been approved through the standard regulatory process.
The FDA regulates human cells and tissues under a framework that distinguishes between “minimally manipulated” products used for their normal function and those that have been significantly altered or repurposed. A stem cell product that is minimally processed and used in its original role in the body (for example, bone marrow transplanted to restore blood cell production) can be marketed with relatively light regulatory oversight. But cells that are cultured, expanded, combined with other substances, or used for a purpose different from their natural function are legally classified as drugs or biological products. That means they need FDA approval before being offered to patients.
Simply being registered with the FDA does not equal approval. The regulations explicitly state that FDA acceptance of an establishment’s registration does not constitute a determination that the establishment is compliant or that its products are licensed.
Enforcement actions have increased in recent years. In January 2025, the Federal Trade Commission and the Georgia Attorney General’s Office announced that the co-founders of the Stem Cell Institute of America were permanently banned from marketing stem cell therapy and ordered to pay more than $5.1 million in civil penalties and consumer refunds. The case, which resulted in summary judgment in favor of the government on all counts, also prohibited the defendants from claiming that any training program they offered was approved by the FTC or FDA. If you are considering a stem cell treatment, the distinction between an FDA-approved therapy and a marketed but unapproved one is a critical legal and safety question.
Where the Legal Boundaries Stand
The short answer is that stem cell research is legal throughout most of the world, but the details depend on what kind of stem cells are involved, who is paying for the research, and where it takes place. In the U.S., the primary federal restriction is a funding limitation, not a criminal ban. Privately funded embryonic research is legal at the federal level, though a handful of states impose their own prohibitions. Adult stem cell and iPSC research face minimal legal barriers anywhere. And for stem cell treatments offered to consumers, the key legal question is whether the product meets the regulatory threshold that requires formal FDA approval before it can be sold.